Skip to main content
Arthritis Research & Therapy logoLink to Arthritis Research & Therapy
. 2014 Sep 18;16(Suppl 1):A35. doi: 10.1186/ar4651

Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients

Sasha Bernatsky 1,, Rosalind Ramsey-Goldman 2, Jean-François Boivin 3, Lawrence Joseph 1, Michelle A Petri 4, Asad Zoma 5, Susan Manzi 6, Murray B Urowitz 7, Dafna D Gladman 7, Paul R Fortin 8, Ellen M Ginzler 9, Edward Yelin 10, Sang-Cheol Bae 11, Daniel J Wallace 12, Steven M Edworthy 13, Soren Jacobsen 14, Caroline Gordon 15, Mary A Dooley 16, Christine A Peschken 17, John G Hanly 18, Graciela S Alarcón 19, Ola Nived 20, Guillermo Ruiz-Irastorza 21, David Isenberg 22, Anisur Rahman 22, Torsten Witte 23, Cynthia Aranow 24, Diane L Kamen 25, Kristján Steinsson 26, Anca Askanase 27, Susan G Barr 13, Lindsey A Criswell 10, Gunnar Sturfelt 20, Neha M Patel 9, Jean-Luc Senécal 28, Michel Zummer 28, Janet E Pope 29, Stephanie Ensworth 30, Hani El-Gabalawy 17, Timothy McCarthy 17, Yvan St Pierre 1, Anne E Clarke 13
PMCID: PMC4179554

Background

Patients with systemic lupus erythematosus (SLE) experience an increased risk of cancer, which is particularly driven by hematological malignancies. Our objective was to determine whether certain factors (demographics, SLE duration and calendar year) were associated with cancer risk in SLE, relative to the general population, using a large multicenter clinical cohort.

Methods

We present detailed analyses of a multisite international SLE cohort (30 centers, 16,409 patients). Cancers were ascertained by registry linkage. Standardized incidence ratios (SIR; ratio of observed to expected cancers) were calculated for overall and for hematological cancer risk, representing the relative risk of cancer for SLE patients, versus the age, sex, and calendar-year-matched general. We used Poisson hierarchical regression to assess for potential independent effects of the factors examined (sex, race/ethnicity, age group, SLE duration, calendar-year period) on the SIRs among the SLE cohort members. The hierarchical nature of the model allowed for differences in effects from one country to the next.

Results

In adjusted analyses (Table 1), we demonstrated lower SIR estimates for overall cancer risk, in black versus white SLE patients, in SLE patients of older versus younger age, and for patients with SLE duration of 5 years or more (versus lower duration). Female sex and calendar year were not clearly associated with any differences in the SIR estimates for SLE patients. Regarding hematological cancer specifically, SLE duration of 5 years or more again appeared to be associated with lower SIR estimates.

Table 1.

Results of adjusted multivariate regression to determine independent effect of variables on SIR* estimates for cancer in SLE

Adjusted effectsa 95% confidence interval
Female sex 1.00 0.77 to 1.30
Race/ethnicity
  White Reference group
  Black 0.75 0.58 to 0.97
  Asian 1.18 0.85 to 1.62
Age
  <40 Reference group
  40 to 59 0.72 0.55 to 0.94
  60+ 0.55 0.42 to 0.73
SLE duration
  <5 years Reference group
  ≥5 years 0.74 0.61 to 0.89
Calendar-year period
  <2000 Reference group
  ≥2000 0.95 0.79 to 1.15

aVariables adjusted concomitantly for all others (sex, race/ethnicity, age, SLE duration, calendar-year period).

Conclusions

Although cancer risk in SLE is increased relative to the general population, patients most at risk appear to be those of white race/ethnicity, younger age, and of shorter SLE duration.


Articles from Arthritis Research & Therapy are provided here courtesy of BMC

RESOURCES